TRIUMPH-4 (retatrutide, 68 weeks): Discontinuation due to AEs: 12.2% (9 mg), 18.2% (12 mg) vs 4.0% placebo Key characteristics: Highest GI adverse event rates among the drugs compared here Dysesthesia is a novel safety signal -- abnormal touch sensations affecting up to 21% at the 12 mg dose, not seen in Phase 2
Glycosaminoglycan synthesis also increased by approximately 70%, contributing to improved skin hydration and volume
Rest assured, we only affiliate with our authorized dispensaries that procure product through reliable sources
Consultations and medications are paid out of pocket, but HSA and FSA funds can typically be applied to qualifying expenses
Kumar TR, Wiseman AL, Kala G, Kala SV, Matzuk MM, Lieberman MW: Reproductive defects in gamma-glutamyl transpeptidase-deficient mice
Figure 8D visually illustrates this specific example